palbociclib

Also known as PD-0332991, PD0332991, PD 332991, PD 0332991, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one

Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy.

Key facts

Drug.image: Palbociclib skeletal formula.svg
Drug.image_class: skin-invert-image
Drug.image2: Palbociclib ball-and-stick model from xtal 2023.png
Drug.image_class2: bg-transparent
Drug.tradename: Ibrance, others
Drug.MedlinePlus: a615013
Drug.DailyMedID: Palbociclib
Drug.pregnancy_AU: D
Drug.routes_of_administration: By mouth
Drug.ATC_prefix: L01
Drug.ATC_suffix: EF01
Drug.legal_AU: S4
Drug.legal_CA: Rx-only
Drug.legal_UK: POM
Drug.legal_US: Rx-only
Drug.legal_EU: Rx-only
Drug.bioavailability: 46%
Drug.protein_bound: 85%

via Wikipedia infobox

Chemical data

Formula: C24H29N7O2
Molecular weight: 447.5 g/mol
IUPAC name: 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-yl-2-pyridinyl)amino]pyrido[2,3-d]pyrimidin-7-one
SMILES: CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C
InChIKey: AHJRHEGDXFFMBM-UHFFFAOYSA-N
XLogP: 1.8
Polar surface area: 103 Å²
H-bond donors: 2
H-bond acceptors: 8
Formal charge: 0

via PubChem

Research

2,869 papers

Palbociclib and Letrozole in Advanced Breast Cancer.The New England journal of medicine · 2016
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.The Lancet. Oncology · 2016
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.Breast cancer research and treatment · 2019
Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study.Journal of global oncology · 2019

via PubMed

Wikidata facts

Mass: 447.238

Show 4 more facts

chemical formula: C₂₄H₂₉N₇O₂
canonical SMILES: CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C
World Health Organisation international non-proprietary name: palbociclib
Commons category: Palbociclib

Sources (6)

via Wikidata · CC0

~16 min read

Article

18 sections

Contents

Mechanism of action
Administration
Approvals and indications
HR+ breast cancer
Adverse effects
Mechanisms of resistance
Resistance to palbociclib
''De novo'' resistance
Resistance due to endocrine therapy
Other mechanisms of resistance
Clinical trials
HR+ breast cancer
Active clinical trials
Drugs with a similar mechanism of action
Society and culture
Economics
Resistance to cost
References

{{Infobox drug | image = Palbociclib skeletal formula.svg | image_class = skin-invert-image | alt = | caption = | image2 = Palbociclib ball-and-stick model from xtal 2023.png | image_class2 = bg-transparent